

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

THE APPLICATION OF: Carter et al.

Assistant Commissioner for Patents

Washington, D.C. 20231

Carter et al. : CASE NO.: PH-7268 10/027,505 : ART UNIT: 1614

SERIAL NO.:

FILED:

December 20,2001:

EXAMINER: Unknown

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 1 3 2002

TECH . JEN 1600/2900

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (X) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below.
 - () The fee of \$240.00 as set forth in \$1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1)

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

Respectfully submitted,

Mary K. VanAtten

May Vant

Attorney for Applicants

Registration No. 39,408


Telephone: 302-467-5268

DATE: June 6, 2002

Bristol-Myers Squibb Company

P. O. Box 4000

Princeton, NJ 08543-4000



OTP E JOS JUN 11 2002 JUN 11 2

Certificate of Mailing under 37 CFR 1.8

In the Application of:

Carter et al.

CASE NO.: **PH-7268**

APPLICATION NO.:

10/027,505

GROUP ART UNIT: 1614

FILED:

DECEMBER 20, 2001

EXAMINER: UNKNOWN

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

I hereby certify that this correspondence, a <u>Information Disclosure Statement</u> is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED
JUN 1 3 2002

on _____ June 7, 2002 Date TECH CENTER 1600/2900

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.